Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction

Journal of Sexual Medicine

Volumn 12, Issue 10, 2015, Pages 2036-2048

  Jacobsen, Paula L ^a   Mahableshwarkar, Atul R ^a   Chen, Yinzhong ^a   Chrones, Lambros ^a   Clayton, Anita H ^b  

^a TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Escitalopram; Major Depressive Disorder; Treatment Emergent Sexual Dysfunction; Vortioxetine

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VORTIOXETINE; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SULFIDE;

ADULT; ANGINA PECTORIS; ANORGASMIA; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; CHANGES IN SEXUAL FUNCTIONING QUESTIONNAIRE SHORT FORM 14; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; EJACULATION DISORDER; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LABORATORY TEST; LIBIDO DISORDER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MESENTERIC VEIN THROMBOSIS; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NEPHROLITHIASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROFILE OF MOOD STATES; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SSRI INDUCED SEXUAL DYSFUNCTION; TREATMENT DURATION; TREATMENT EMERGENT SEXUAK DYSFUNCTION; TREATMENT RESPONSE; VITAL SIGN; VOMITING; ADOLESCENT; AGED; CANADA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION; DRUG EFFECTS; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CANADA; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SULFIDES; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84945438444     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12980     Document Type: Article

References (52)

1. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012;21:169-184.
2. American Psychiatric Association. Work group on major depressive disorder. Practice guideline for the treatment of patients with major depressive disorder. third edition. Arlington, VA: American Psychiatric Association; 2010.
3. Williams K, Reynolds MF. Sexual dysfunction in major depression. CNS Spectr 2006;11:19-23.
4. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67(suppl 6):33-37.
5. Corona G, Ricca V, Bandini E, Mannucci E, Lotti F, Boddi V, Rastrelli G, Sforza A, Faravelli C, Forti G, Maggi M. Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med 2009;6:1259-1269.
6. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007;4:917-929.
7. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366.
8. Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-692.
9. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(suppl 3):10-21.
10. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: A critical review. J Clin Psychopharmacol 1999;19:67-85.
11. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol 2009;29:259-266.
12. Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: Replication in a cross-sectional patient survey. J Psychopharmacol 2010;24:489-496.
13. Ashton AK, Rosen RC. Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Marital Ther 1998;24:191-192.
14. Liang CS, Ho PS, Chiang KT, Su HC. 5-HT2A receptor-1438 G/A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: A prospective exploratory study. J Sex Med 2012;9:2009-2016.
15. Sidi H, Asmidar D, Hod R, Guan NC. Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine. J Sex Med 2012;9:1392-1399.
16. Clayton AH, El Haddad S, Iluonakhamhe JP, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf 2014;13:1361-1374.
17. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013;(5):CD003382.
18. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: Impact, effects, and treatment. Drug Healthc Patient Saf 2010;2:141-150.
19. Rizvi SJ, Kennedy SH. Management strategies for SSRI-induced sexual dysfunction. J Psychiatry Neurosci 2013;38:E27-28.
20. Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: Mechanisms and clinical implications. Postgrad Med 2014;126:91-99.
21. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: An updated meta-analysis. Ann Intern Med 2011;155:772-785.
22. Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis. Drug Saf 2014;37:19-31.
23. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB. Discovery of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54:3206-3221.
24. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22:482-491.
25. Boulenger J-P, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20mg/day: A randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014;29:138-149.
26. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012;73:953-959.
27. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013;29:217-226.
28. Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi M. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015;232:2061-2070.
29. Jain R, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 2013;16:313-321.
30. Lexapro [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2011.
31. Sheehan D, Janavs J, Harnett-Sheehan K, Sheehan M, Gray C, Lecrubier Y, Weiller E, Hergueta T, Allgulander C, Kadri N, Baldwin D, Even C: M.I.N.I.: Mini International Neuropsychiatric Interview, English version 6.0.0 (DSM-IV). 2009.
32. Guy W (ed). Clinical Global Impressions (028-CGI). In Revised, ed. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; 1976:217-222.
33. Keller A, McGarvey EL, Clayton AH. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther 2006;32:43-52.
34. Clayton AH, McGarvey EL, Clavet GJ, Piazza L. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 1997;33:747-753.
35. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability, and validity. Psychopharmacol Bull 1997;33:731-745.
36. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
37. McNair DM, Lorr M, Droppleman LF. EdITS manual for the profile of mood states. San Diego, CA: Educational and Industrial Testing Service; 1971.
38. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-1277.
39. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006;26:482-488.
40. Jacobsen P, Clayton A, Mahableshwarkar A, Palo W, Chen Y, Dragheim M. The effect of vortioxetine on sexual dysfunction during the treatment of adults with major depressive disorder (MDD) or generalized anxiety disorder (GAD) [abstract]. Poster presented at 54th Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP/NCDEU), June 16-19, 2014; Hollywood, FL.
41. Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014;29:470-482.
42. Lepola UM, Loft H, Reines EH. Escitalopram (10-20mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-217.
43. Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102.
44. Bech P, Tanghoj P, Cialdella P, Andersen HF, Pedersen AG. Escitalopram dose-response revisited: An alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004;7:283-290.
45. Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C. Escitalopram maintenance treatment for prevention of recurrent depression: A randomized, placebo-controlled trial. J Clin Psychiatry 2006;67:1767-1775.
46. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacol Ther 2015;145:43-57.
47. Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T, Lanzenberger R, Spindelegger C, Holik A, Asenbaum S, Dudczak R, Tauscher J, Kasper S. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: An [123I]ADAM SPECT study. Psychopharmacology (Berl) 2007;191:333-339.
48. Kreilgaard M, Smith DG, Brennum LT, Sanchez C. Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice. Br J Pharmacol 2008;155:276-284.
49. Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: A review of the clinical evidence and the possible mechanisms involved. Front Pharmacol 2013;4:1-10.
50. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol 2006;20:91-96.
51. Baldwin DS, Palazzo MC, Masdrakis VG. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depress Res Treat 2013;2013:256841.
52. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012;26:1408-1416.